Diarrhea and skin toxicity are the most common AEs of EGFR-TKIs35, while hypertension, proteinuria, hemorrhage and arterial thromboembolic events are the most common AEs in patients treated with angiogenesis inhibitors. This evidence concerns the gene EGFR and Hypertension.